Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Southwest Synthetic Pharmaceutical To Consolidate Founder Group’s Pharmaceutical Business

This article was originally published in PharmAsia News

Executive Summary

Southwest Synthetic Pharmaceutical has announced plans to issue additional shares to Peking University International Hospital to acquire the latter's subsidiary Chongqing Daxin Pharmaceutical. Southwest Synthetic and Peking University International Hospital are both subsidiaries of China's IT giant Founder Group. Sources disclose that the conglomerate will transfer its 87.65 percent stake in Daxin Pharmaceutical to Southwest Synthetic, such that all of its pharmaceutical assets are consolidated within one entity. Founder's strategy is to develop IT, pharmaceutical and health care as its main core businesses. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts